13F Holdings
中文EN

NCEL NewcelX Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1783036 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-15.3%
TTM EPS YoY-11.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-134.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets36.7%
Debt / equity0.00x
Current ratio0.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.33x
Accruals ratio-89.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$1.13M$992,000$1.61M$8.98M$5.92M
SG&A expense$1.35M$805,000$1.33M$6.51M$5.94M
Operating income-$2.56M-$2.07M-$3.02M-$15.48M-$11.86M
Interest expense—$45,054$119,920$95,211$48,100
Pretax income—-$7.20M-$3.28M——
Net income-$8.30M-$7.20M-$3.33M-$16.50M-$11.95M
EBITDA-$2.51M-$1.65M-$2.40M-$15.47M-$11.85M
EPS (basic)2.162.431.13-33.52-1.00
EPS (diluted)2.162.431.13-33.52-1.00
Weighted avg. shares (diluted)3.84M2.96M2.96M492,06611.90M
Balance sheet
Cash & equivalents$2.20M$650,000$1.15M$1.97M$5.43M
Current assets$3.18M$780,000$1.82M$9.25M$5.72M
PP&E, net$95,000$123,000$6,694$18,102$29,510
Goodwill$1.73M————
Total assets$11.45M$903,000$1.85M$9.28M$5.76M
Current liabilities$4.20M$8.90M$7.92M$3.36M$2.40M
Short-term debt$355,000$7.73M———
Total liabilities$4.20M$8.90M$10.68M$6.00M$5.22M
Shareholders' equity$7.25M-$8.00M-$1.20M$111,000$542,388
Shares outstanding4.80M2.96M810,72232.43M16.22M
Cash flow statement
Operating cash flow-$2.77M-$1.07M-$3.44M-$13.88M-$14.94M
Capital expenditure$8,000$6,000$6,000—$39,560
Free cash flow-$2.77M-$1.07M-$3.45M—-$14.98M
Investing cash flow$1.70M-$6,000$103,000—-$39,560
Financing cash flow$2.63M$450,000$2.85M$17.40M$20.34M
Depreciation & amortization$55,000$413,000$620,000$11,408$10,050
Stock-based compensation$765,000$208,000$149,000$22,730—

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.